Zhongguancun Subsidiary's Trazodone Hydrochloride Extended-Release Tablets Marketing Authorization Application Accepted

Regulation
โดย 财中社·Read original
Summary · why it matters

Zhongguancun announced that the marketing authorization application for trazodone hydrochloride extended-release tablets from its subsidiary Beijing Huasu Pharmaceutical has been accepted. The drug is used to treat depression with or without anxiety symptoms. As of the announcement date, the project has accumulated research and development expenses of 5.35 million yuan. In the first quarter of 2026, Zhongguancun achieved revenue of 472 million yuan, with a net loss attributable to the parent company of 16.25 million yuan.

Impact on stocks 1

Others▲ · 1 stocks

Off-coverage companies 1

北京华素制药股份有限公司Private▲ Positive
Technologyrelevance

Subsidiary Beijing Huasu Pharmaceutical's drug application accepted, directly advancing its product development.

© 2026 MarketDXNews